

Advances in Pancreatic Cancer



Vincent Chung, MD, FACP 20th Annual California Cancer Consortium The Langham Hotel, Pasadena, CA August 24, 2024

Overview

Scope of the problem

Progress in the treatment of pancreatic cancer

2024 ASCO Updates



Scope of the Problem






Worst survival of any solid tumor

2024 US estimation

- 66,440 new cases
- 51,750 deaths


National Cancer Institute. SEER Stat Fact Sheets: Pancreas.







Adjuvant Therapy for Pancreatic Cancer



Median OS 20.2 vs 22.1 mo


City of Hope.

Median OS 25.5 vs 28 mo

Median OS 35 vs 54.4 mo

APACT Trial of adjuvant gemcitabine and nab-paclitaxel did not meet its primary endpoint


Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer






Rojas LA, et al. Nature 2023.


Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer



GVAX+nivolumab+urelumab meets the primary endpoint by significantly increasing intratumoral CD8+ CD137+ cells




Median disease-free 13.90/14.98/33.51 months Overall survival 23.59/27.01/35.55 months





Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial



D.

Pt. 18

200 µm

Pt. 2

N | Normal tissue


Tumor infiltrating CD3⁺

Tumor peripheral CD3*

minimal residual mKRAS disease (ctDNA and/or serum tumor antigen)

Pant S, et al. Nature 2024.

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial



HR: 0.1420 (0.0321-0.6278)

mKRAS T cell response correlates to tumor biomarker response and delayed tumor recurrence

We are currently testing a 7 KRAS lipid conjugated peptide variant in a randomized phase 2 study



Detecting pancreatic cancer early can save lives





- Pancreatic Cancer Detection Consortium U01
 - International collaboration
 - Blood test for early detection
 - Free-floating and exosome-packaged microRNAs
 - Exosomes from each organ are stamped with a unique mark, like a ZIP code, allowing researchers to zero in on exosomes made by the pancreas.
 - High risk individuals: chronic pancreatitis or new-onset diabetes
 - Early results showed that combining the blood test with CA19-9 accurately identified 97% of the people with early stage pancreatic cancer (presented at AACR 2024)

Neoadjuvant Treatment

- Provides early treatment of micrometastatic disease
- Opportunity to downstage tumors to make them resectable
- Avoids surgery in patients with rapidly progressive disease

- Challenges
 - Chemotherapy is toxic and some patients are unable to tolerate
 - Resectable disease can become unresectable if complications from chemotherapy prevent treatment










Springfield C, et al. Nat Rev Clin Onc. 2023

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial





City of Hope.




PED. BL TIER.											
Resectable, upfront surgery	68 (0)	55 (D)	40 (0)	30 (0)	23 (0)	22 (0)	14(1)	10 (2)	7 (3)	5 (4)	4 (4)
Resectable, neoadjuvant CRT	65 (0)	53 (D)	39 (0)	28 (0)	25 (0)	22 (0)	20 (0)	16 (2)	14 (4)	9 (8)	5(11)
Borderline, upfront surgery	59 (Q)	48 (D)	35 (0)	21 (0)	17 (0)	10 (0)	6 (0)	6 (0)	4 (1)	2 (2)	1 (2)
Borderline, neoadjuvant CRT	54 (0)	45 (0)	34 (0)	25 (0)	21 (0)	17 (0)	14 (0)	13 (0)	10 (1)	8(2)	6 (4)

В


- April 2013 and July 2017
- 246 eligible patients
 - Median overall survival by ITT was 16.0 months with preoperative chemoradiotherapy and 14.3 months with immediate surgery
- More benefit in borderline
 resectable patients

Neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy in the PREOPANC-2 trial (ESMO Congress 2023, LBA83)



Arm B: Neoadjuvant gemcitabine chemoradiotherapy and adjuvant gemcitabine

Overall Survival




ty of Hope.

<u>Median (</u>	OS
FFX	21.9 (17.7-27.0)
CRT	21.3 (16.8-25.5)
<u>1-year C</u>	9 <u>5</u>
FFX	75.7%
CRT	69.6%
<u>2-year C</u>	2 <u>S</u>
FFX	48.6%
CRT	45.7%
<u>3-year C</u>	9 <u>5</u>
FFX	35.6%
CRT	32.8%

- No overall (OS) benefit
- Median OS was 21.9% versus 21.3%
- Resection rates 77% versus 75%
- Serious adverse rates (49% versus 43%, respectively; p=0.26) were also similar between treatment arms

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial




Arm 2: Adjuvant mFOLFIRINOX

	Celiac axis	Superior mesenteric artery	Common hepatic artery	Superior mesenteric vein / portal vein
Resectable (all four required)	no contact	no contact	no contact	≤ 90° contact
Borderline Resectable (minimally one required)	≤ 90° contact	≤ 90° contact	≤ 90° contact	> 90–270° contact and no occlusion
Locally Advanced (minimally one required)	contact > 90°	contact > 90°	contact > 90°	contact > 270° or occlusion



Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer




- Answer the question of chemotherapy timing for patients with resectable PDAC
- Consider accruing to this trial

Cityof Hope.

PI: Cristina R Ferrone, MD: NCT04340141

Management of Advanced Pancreatic Cancer



4-drug chemotherapy regimen is better then a 2-drug regimen

Cityof Hope.

Conroy T, et al. NEJM 2011; Von Hoff D, et al. NEJM 2013; Wainberg Z, et al Lancet 2023.


Toxicity Profile

Grade 3/4 toxicity	Neutropenia	Fatigue	Diarrhea	Neuropathy
Gemcitabine + nab-paclitaxel	38%(25%)	17%(<mark>5%</mark>)	6%(<mark>5%</mark>)	17%(<mark>6%</mark>)
FOLFIRINOX (not modified)	45.7%	23.6%	12.7%	9%
NALIRIFOX	14%	6%	20%	3%


- mFOLFIRINOX, NALIRIFOX or gemcitabine + nab-paclitaxel are appropriate first line treatments for patients with metastatic disease
- Gemcitabine still standard for poor performance status pts

City of Hope.

COMPASS: Comprehensive Molecular Characterization of Advanced **Pancreatic Ductal Adenocarcinoma for Better Treatment Selection**



City of Hope.




Survival ≤3 mo

250

300


- Enhanced RAS signaling
- Deregulation of the PI3K/AKT/mTOR pathway
- Basal-like transcriptomic subtype.

Basal subtype overall worse prognosis compared to classical subtype





Pancreatic adenocarcinoma signature stratification for treatment-01




PASS-01 Schema: Randomized phase II trial (n = 150)

+Eligible histological variants to also include mucinous adenocarcinoma or adenosquamous carcinoma


City of Hope.

PASS-01 PFS (Primary Endpoint)



🕅 Cityof Hope.

56% (64/114) patients were able to receive 2nd-line treatment: a correlate-guided approach was delivered in 50% (32/64)



Correlate-guided Therapy (20 by genomics, 12 by PDOs over 28 Molecular Tumor Boards)




PRESENTED BY: Dr Jennifer J Knox

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org




NRG Oncology/RTOG 0848: Adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma



City of Hope.

NRG Oncology/RTOG 0848: Adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma




Overall Survival

Disease-Free Survival

No difference in OS and DFS




NRG Oncology/RTOG 0848: Adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma




Chemo CRT improved OS and DFS in the node-negative patients Limitations: Gemcitabine is an inferior adjuvant therapy



ECOG-ACRIN EA2186 (GIANT Trial)




ECOG-ACRIN EA2186 (GIANT Trial)



No difference in OS and PFS

OS of 4.7 and 4.4 months is worse than expected in this population of vulnerable older adults

Cityof Hope.








Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies Were Announced in Press Release July 31, 2024


Pamrevlumab - human monoclonal antibody targeting ٠ connective tissue growth factor (CTGF) with potential anti-fibrotic and antineoplastic activities.



Shen YW, et al Trends in Mol Med. 2020.

- LAPIS (284 pt): Gemcitabine and nabpaclitaxel or oxaliplatin, folinic acid, irinotecan, and fluorouracil (FOLFIRINOX) with and without pamrevlumab. Median OS was 17.3 months in the pamrevlumab arm vs 17.9 months in the comparator arm (HR, 1.08; 95% CI, 0.83-1.41; stratified log-rank P =.55).
- **Precision Promise (825 pt)**: Pamrevlumab • plus gemcitabine and nab-paclitaxel vs gemcitabine and nab-paclitaxel alone in firstand second-line metastatic pancreatic ductal adenocarcinoma (PDAC). No improvement in OS (HR, 1.170; 95% CI, 0.882-1.563; P =.13977)

Final Thoughts



- Accelerating progress in pancreatic cancer research
- Molecular subtypes of pancreatic cancer have different biologies
- Targeted treatments improve overall survival
- Novel trial designs will help accelerate drug development in pancreatic cancer

